Spero Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
SPRO$1.07+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
The prearranged written stock sale plan adopted in accordance with Rule 10b5-1 of the Exchange Act of Satyavrat Shukla, our President and Chief Executive Officer, terminated by its terms on February 15, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.